← Leaderboards
Barbara Stauch Slusher
Johns Hopkins University
$18,499,514
Attributed
$36,293,625
Total exposure
23
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.9M · FY2011–25$10M$7.5M$5M$2.5M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$42,207,288 · 24
By mechanism
R01$25,740,515 · 11
P30$8,743,786 · 4
R25$3,720,694 · 3
P01$1,704,740 · 1
R61$1,603,717 · 2
R33$409,336 · 1
Top collaborators
- Takashi Tsukamoto18 shared
- Kannan Rangaramanujam17 shared
- Michael A. Rogawski14 shared
- Karl A Scheidt10 shared
- Sujatha Kannan9 shared
- Rana Rais9 shared
- Amy F.T. Arnsten5 shared
- Marcie A Glicksman5 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Martin G Pomper$38,517,075
- Kannan Rangaramanujam$10,355,612
- Shawn Lupold$4,097,268
- Takashi Tsukamoto$11,312,957
- Ronald Rodriguez$1,548,652
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposDrug KineticsDrug DiscoveryDoseBrainIn VivoBaseEnzymesCellsExhibitsMouse ModelPharmaceutical PreparationsIn VitroLeadGlutamatesMetabolicDesignFutureClinical TrialsPharmaceutical ChemistryPlayResearch PersonnelInhibitor/AntagonistSeries
Grant awards (89)
JHU Center for the Advancement of HIV Neurotherapeutics (JHU CAHN)$1,456,064
P30 · FY2025 · MH
Development of neutral sphingomyelinase 2 (nSMase2) inhibitors for the treatment of Alzheimer's disease$710,695
R01 · FY2025 · AG
Evaluating and Optimizing Novel nSMase2 Inhibitors in the Treatment of Cancers$680,034
R01 · FY2025 · CA
Macrophage-targeted dendrimer 2-PMPA for the treatment of age-related sarcopenia$540,506
R01 · FY2025 · AG · contact PI
Targeting glutamate carboxypeptidase in perinatal brain injury$518,490
R01 · FY2025 · NS
JHU Center for the Advancement of HIV Neurotherapeutics (JHU CAHN)- Therapeutic Core$416,007
P30 · FY2025 · MH · contact PI
Development of NAT8L inhibitors for the Treatment of Canavan Disease$393,942
R61 · FY2025 · NS
Training in Neurotherapeutics for Academic Scientists$268,200
R25 · FY2025 · NS
JHU Center for the Advancement of HIV Neurotherapeutics (JHU CAHN)$1,471,424
P30 · FY2024 · MH
Development of GCPII inhibitors for the treatment of age-related cognitive disorders$784,969
R01 · FY2024 · AG
Evaluating and Optimizing Novel nSMase2 Inhibitors in the Treatment of Cancers$695,916
R01 · FY2024 · CA
Development of neutral sphingomyelinase 2 (nSMase2) inhibitors for the treatment of Alzheimer's disease$683,930
R01 · FY2024 · AG
Macrophage-targeted dendrimer 2-PMPA for the treatment of age-related sarcopenia$580,168
R01 · FY2024 · AG · contact PI
Targeting glutamate carboxypeptidase in perinatal brain injury$552,328
R01 · FY2024 · NS
JHU Center for the Advancement of HIV Neurotherapeutics (JHU CAHN)- Therapeutic Core$459,692
P30 · FY2024 · MH · contact PI
Development of NAT8L inhibitors for the Treatment of Canavan Disease$396,324
R61 · FY2024 · NS
Training in Neurotherapeutics for Academic Scientists$268,200
R25 · FY2024 · NS
JHU Center for the Advancement of HIV Neurotherapeutics (JHU CAHN)$1,486,194
P30 · FY2023 · MH
Development of GCPII inhibitors for the treatment of age-related cognitive disorders$784,616
R01 · FY2023 · AG
Development of neutral sphingomyelinase 2 (nSMase2) inhibitors for the treatment of Alzheimer's disease$651,180
R01 · FY2023 · AG
Targeting glutamate carboxypeptidase in perinatal brain injury$571,782
R01 · FY2023 · NS
Macrophage-targeted dendrimer 2-PMPA for the treatment of age-related sarcopenia$518,067
R01 · FY2023 · AG · contact PI
Dendrimer-conjugated nSMase2 inhibitor as a novel therapeutic approach for Alzheimer's Disease$471,402
R01 · FY2023 · AG
JHU Center for the Advancement of HIV Neurotherapeutics (JHU CAHN)- Therapeutic Core$424,194
P30 · FY2023 · MH · contact PI
High Throughput Screen for Discovery of N-Acetyltransferase 8 Like (NAT8L) Inhibitors$409,336
R33 · FY2023 · NS · contact PI
Training in Neurotherapeutics for Academic Scientists$268,401
R25 · FY2023 · NS
JHU Center for the Advancement of HIV Neurotherapeutics (JHU CAHN)$1,499,981
P30 · FY2022 · MH
Development of GCPII inhibitors for the treatment of age-related cognitive disorders$828,290
R01 · FY2022 · AG
Targeting glutamate carboxypeptidase in perinatal brain injury$537,837
R01 · FY2022 · NS
Dendrimer-conjugated nSMase2 inhibitor as a novel therapeutic approach for Alzheimer's Disease$526,162
R01 · FY2022 · AG
Cell-targeted glutamine antagonists as a novel therapy for lymphoma$486,249
R01 · FY2022 · CA · contact PI
Macrophage-targeted dendrimer 2-PMPA for the treatment of age-related sarcopenia$476,442
R01 · FY2022 · AG · contact PI
JHU Center for the Advancement of HIV Neurotherapeutics (JHU CAHN)- Therapeutic Core$425,832
P30 · FY2022 · MH · contact PI
High throughput screen for discovery of N-acetyltransferase 8 Like (NAT8L) inhibitors$404,097
R61 · FY2022 · NS · contact PI
Regulation of Exosome Secretion as a novel therapeutic approach for Alzheimer's Disease$401,436
R01 · FY2022 · AG · contact PI
Training in Neurotherapeutics for Academic Scientists$270,000
R25 · FY2022 · NS
Development of GCPII inhibitors for the treatment of age-related cognitive disorders$704,994
R01 · FY2021 · AG
Cell-targeted glutamine antagonists as a novel therapy for lymphoma$496,172
R01 · FY2021 · CA · contact PI
Regulation of Exosome Secretion as a novel therapeutic approach for Alzheimer's Disease$492,421
R01 · FY2021 · AG · contact PI
Dendrimer-conjugated nSMase2 inhibitor as a novel therapeutic approach for Alzheimer's Disease$458,867
R01 · FY2021 · AG
Novel brain penetrant metabolic inhibitors to treat MYC-driven medulloblastoma$456,591
R01 · FY2021 · NS · contact PI
High throughput screen for discovery of N-acetyltransferase 8 Like (NAT8L) inhibitors$409,354
R61 · FY2021 · NS · contact PI
Training in Neurotherapuetics and Development for Academic Scientists$264,890
R25 · FY2021 · NS
Development of GCPII inhibitors for the treatment of age-related cognitive disorders$720,931
R01 · FY2020 · AG
Regulation of Exosome Secretion as a novel therapeutic approach for Alzheimer's Disease$492,421
R01 · FY2020 · AG · contact PI
Cell-targeted glutamine antagonists as a novel therapy for lymphoma$452,939
R01 · FY2020 · CA · contact PI
Glutaminase Inhibitor Drug Discovery and Nanoparticle-Based Delivery for Pancreatic Cancer Therapy$417,346
R01 · FY2020 · CA · contact PI
Targeting glutamate carboxypeptidase in perinatal brain injury$408,400
R01 · FY2020 · NS
Novel brain penetrant metabolic inhibitors to treat MYC-driven medulloblastoma$384,346
R01 · FY2020 · NS · contact PI
Dendrimer-conjugated nSMase2 inhibitor as a novel therapeutic approach for Alzheimer's Disease$378,916
R01 · FY2020 · AG
TRAINING IN NEUROTHERAPUETICS AND DEVELOPMENT FOR ACADEMIC SCIENTISTS$264,890
R25 · FY2020 · NS
Regulation of Exosome Secretion as a novel therapeutic approach for Alzheimer's Disease$492,421
R01 · FY2019 · AG
Cell-targeted glutamine antagonists as a novel therapy for lymphoma$439,350
R01 · FY2019 · CA · contact PI
Targeting glutamate carboxypeptidase in perinatal brain injury$408,400
R01 · FY2019 · NS
Glutaminase Inhibitor Drug Discovery and Nanoparticle-Based Delivery for Pancreatic Cancer Therapy$406,798
R01 · FY2019 · CA · contact PI
Novel brain penetrant metabolic inhibitors to treat MYC-driven medulloblastoma$384,361
R01 · FY2019 · NS · contact PI
Therapeutic Core$336,952
P30 · FY2019 · MH · contact PI
TRAINING IN NEUROTHERAPUETICS AND DEVELOPMENT FOR ACADEMIC SCIENTISTS$265,032
R25 · FY2019 · NS
Intranasal Insulin Therapy for HIV-Associated Neurocognitive Disorders: Preclinical Evaluation$238,852
P01 · FY2019 · MH · contact PI
Regulation of Exosome Secretion as a novel therapeutic approach for Alzheimer's Disease$492,421
R01 · FY2018 · AG
Targeting glutamate carboxypeptidase in perinatal brain injury$458,089
R01 · FY2018 · NS
Cell-targeted glutamine antagonists as a novel therapy for lymphoma$452,939
R01 · FY2018 · CA · contact PI
Glutaminase Inhibitor Drug Discovery and Nanoparticle-Based Delivery for Pancreatic Cancer Therapy$425,618
R01 · FY2018 · CA · contact PI
Novel brain penetrant metabolic inhibitors to treat MYC-driven medulloblastoma$384,361
R01 · FY2018 · NS · contact PI
Therapeutic Core$374,305
P30 · FY2018 · MH · contact PI
TRAINING IN NEUROTHERAPUETICS AND DEVELOPMENT FOR ACADEMIC SCIENTISTS$267,733
R25 · FY2018 · NS
Intranasal Insulin Therapy for HIV-Associated Neurocognitive Disorders: Preclinical Evaluation$258,292
P01 · FY2018 · MH · contact PI
Targeting glutamate carboxypeptidase in perinatal brain injury$434,678
R01 · FY2017 · NS
Glutaminase Inhibitor Drug Discovery and Nanoparticle-Based Delivery for Pancreatic Cancer Therapy$425,618
R01 · FY2017 · CA · contact PI
Therapeutic Core$393,141
P30 · FY2017 · MH · contact PI
Intranasal Insulin Therapy for HIV-Associated Neurocognitive Disorders: Preclinical Evaluation$371,983
P01 · FY2017 · MH · contact PI
TRAINING IN NEUROTHERAPUETICS AND DEVELOPMENT FOR ACADEMIC SCIENTISTS$268,551
R25 · FY2017 · NS
Targeting glutamate carboxypeptidase in perinatal brain injury$443,366
R01 · FY2016 · NS
Intranasal Insulin Therapy for HIV-Associated Neurocognitive Disorders: Preclinical Evaluation$427,298
P01 · FY2016 · MH · contact PI
Glutaminase Inhibitor Drug Discovery and Nanoparticle-Based Delivery for Pancreatic Cancer Therapy$425,618
R01 · FY2016 · CA · contact PI
GCPII Inihibitors for the treatment of chemotherapy-induced neuropathy$365,161
R01 · FY2016 · CA · contact PI
Training in Neurotherapeutics Discovery and Development for Academic Scientists$261,858
R25 · FY2016 · NS
Intranasal Insulin Therapy for HIV-Associated Neurocognitive Disorders: Preclinical Evaluation$408,315
P01 · FY2015 · MH · contact PI
GCPII Inihibitors for the treatment of chemotherapy-induced neuropathy$381,996
R01 · FY2015 · CA · contact PI
Training in Neurotherapeutics Discovery and Development for Academic Scientists$262,693
R25 · FY2015 · NS
GCPII Inihibitors for the treatment of chemotherapy-induced neuropathy$382,443
R01 · FY2014 · CA · contact PI
Training in Neurotherapeutics Discovery and Development for Academic Scientists$263,345
R25 · FY2014 · NS
GCPII Inihibitors for the treatment of chemotherapy-induced neuropathy$342,087
R01 · FY2013 · CA · contact PI
Training in Neurotherapeutics Discovery and Development for Academic Scientists$257,513
R25 · FY2013 · NS
GCPII Inihibitors for the treatment of chemotherapy-induced neuropathy$329,947
R01 · FY2012 · CA · contact PI
Training in Neurotherapeutics Discovery and Development for Academic Scientists$269,388
R25 · FY2012 · NS
Identification of novel system xc- inhibitors$202,500
R21 · FY2012 · NS · contact PI
HTS Screening for Glutaminase Inhibitors$41,000
R03 · FY2012 · DA · contact PI
HTS Screening for Glutaminase Inhibitors$41,000
R03 · FY2011 · DA · contact PI